Polyglycerol Derivative for Use in Diagnosing a Disease at an Early Stage

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention discloses the use of dendritic polyglycerol derivatives, which can be chemically modified and attached to diagnostic molecules, for the early-stage diagnosis of diseases. These polyglycerol-based agents specifically bind to markers of early disease processes, such as angiogenesis, extracellular matrix remodeling, and activated lymph nodes, thereby allowing detection before clinical symptoms appear. The invention enables site-specific imaging using various diagnostic modalities (such as optical imaging, PET, SPECT, and MRI) by delivering the contrast or tracer to relevant pathological sites at the earliest stages of disease.

Use CasesContent extracted from patent full text and abstract with AI.

• Early detection of cancers by imaging tumor angiogenesis before tumors become clinically apparent.
• Monitoring and diagnosing inflammatory diseases such as arthritis, colitis, inflammatory skin disease, myelitis, encephalitis, and pneumonitis.
• Detecting and tracking activated lymph nodes to determine disease spread or staging, especially in cancer or infectious diseases.
• Tracking disease progression or therapeutic response by repeated imaging of extracellular matrix remodeling over time.
• Non-invasive imaging and tracking of specific cell populations in vivo for research or diagnostic purposes.
• Improved detection of diseases related to reperfusion injuries by visualizing early changes in tissue structure.

BenefitsContent extracted from patent full text and abstract with AI.

• Allows for disease diagnosis at very early, pre-symptomatic stages, improving chances of successful treatment and management.
• High specificity and sensitivity due to targeting of disease-relevant biological processes and enzymes like heparanase.
• Compatible with multiple imaging modalities (optical, optoacoustic, PET, SPECT, MRI), providing flexible diagnostic options.
• Reduces the likelihood of false positives and provides more detailed information about exact disease staging and spread.
• Enables continuous monitoring and tracking of disease progression or therapeutic response with higher precision.
• Potentially lower cost and better pharmacokinetic profile compared to traditional macromolecular diagnostic agents due to optimized molecular design.
• Facilitates personalized medicine by enabling tailored treatment decisions based on highly specific diagnostic information.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to a further medical use of a polyglycerol derivative, namely to a use for diagnosing a disease at an early stage of the disease by site-specific imaging of angiogenesis, of extracellular matrix remodeling and/or of activated lymph nodes in a human or an animal, wherein the early stage of the disease is characterized by the absence of obvious clinical symptoms due to the disease. Thereby, the polyglycerol derivative comprises a dendritic polyglycerol backbone comprising a plurality of hydroxyl groups that are optionally at least partly substituted by sulfate groups; and a diagnostic effector residue.